Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J0XN
|
|||
| Former ID |
DIB011710
|
|||
| Drug Name |
OpRegen
|
|||
| Synonyms |
HESC-derived RPEs (AMD), Cell Cure/Hadasit/Hadassah; Human embryonic stem cell-derived retinal pigmented epithelial cells (age-related macular degeneration), Cell Cure/Hadasit/Hadassah
Click to Show/Hide
|
|||
| Drug Type |
Human embryonic stem (hES) cell-derived therapeutics
|
|||
| Indication | Dry age-related macular degeneration [ICD-11: 9B75; ICD-10: H35.31] | Phase 1/2 | [1] | |
| Company |
Cell Cure Neuroscience
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02286089) Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.